ArticleOncoimmunology2026
Broad targeting of HPV E proteins by intratumoral and systemic B cell responses in HPV+ head and neck cancer.
Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
B cells can account for a substantial proportion of tumor-infiltrating lymphocytes (TILs) and have been associated with improved outcomes in several malignancies. Yet, their antigen specificity, a key factor for ascribing a distinct function, is mostly unknown. Here, we demonstrate that in tumors of patients with human papillomavirus-positive head and neck cancer (HPV+ HNC) a substantial proportion of intratumoral antibody-secreting cells (ASCs) are specific for HPV E proteins. Using IgG ELISpots on TILs, we show that HPV E protein-specific ASCs are detectable in virtually all patients and can account for up to almost a third of all intratumoral IgG+ ASCs. ASC responses against the viral proteins E1 and E2 consistently outnumbered those against the classic oncoproteins E6 and E7. HPV-specific intratumoral ASCs correlated strongly between primary tumor and metastatic lymph nodes as well as with plasma IgG titers, indicating that intratumoral tumor-specific ASCs, at least partially, contribute to systemic anti-tumor responses. To further resolve the makeup of tumor-specific antibody responses, we developed a novel Multiplex Antigen Flow-based ImmunoAssay (MAFIA) enabling simultaneous and standardized quantification of HPV E-specific antibodies across all major Ig isotypes and IgG subclasses. Applying MAFIA to plasma samples of patients with HPV+ HNC revealed that HPV-specific plasma antibodies mainly consisted of IgG1, IgG3, and IgA, with the highest median responses directed against E1 and E2. Overall, our study delineates the antigenic hierarchy and makeup of HPV-specific humoral responses in HPV+ HNC, both intratumorally and systemically, thus providing a framework for future biomarker as well as next-generation therapeutics development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.